Company intelligence / Profile preview

Renexxion

Ownership: Private
Development stage: Phase 3

Overview

Renexxion’s lead compound naronapride is a highly selective dual-action small molecule designed to enhance GI motility with minimal systemic absorption. It is currently being evaluated in a global Phase 2b trial (“MOVE‑IT”) for gastroparesis, with enrollment ongoing in both Europe and the United States. The company has also received FDA IND clearance to study naronapride as a treatment for PPI-nonresponsive GERD. Naronapride has shown efficacy across multiple GI motility disorders and may address significant unmet needs where current therapies are inadequate or unavailable.

Therapeutic areas: Gastroenterology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

naronapride

Partnerships

Dr Falk Pharma GmbH – strategic partner for joint development/commercialization of naronapride across Greater Europe, Russia, Central Asian Republics & parts of Australasia.Potential future licensing/collaboration partnerships targeted for Greater China & Japan.

Beyond the preview

Go deeper on Renexxion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renexxion.